REG - Proteome Sciences - Notice of Results and Investor Presentation

Proteome SciencesAnnouncement

04/04/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250404:nRSD7545Da&default-theme=true

RNS Number : 7545D  Proteome Sciences PLC  04 April 2025

 

 

 
 
4 April 2025

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Notice of Results and Investor Presentation

 

Proteome Sciences (AIM: PRM) announces that the Company's results for the year
ending 31 December 2024 will be announced on 10 April 2025 (the "Final
Results"). The Company looks forward to updating shareholders on the Company's
performance and on the outlook for 2025.

 

On the 11 April 2025 at 10:30 BST the Company's Executive Chairman,
Christopher Pearce and Dr Ian Pike, the Chief Scientific Officer (CSO), will
provide a live presentation relating to the Final Results via Investor Meet
Company.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
10 April 2025, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Proteome Sciences via:
https://www.investormeetcompany.com/proteome-sciences-plc/register-investor
(https://www.investormeetcompany.com/proteome-sciences-plc/register-investor)

 

Investors who already follow Proteome Sciences on the Investor Meet Company
platform will automatically be invited.

 

 

For further information please contact:

 Proteome Sciences plc
 Dr. Ian Pike, Chief Scientific Officer                                         Tel: +44 (0)20 7043 2116
 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale/Lauren Wright (Corporate Finance)                              Tel: +44 (0) 20 3328 5656

 Tony Quirke/Stefano Aquilino (Equity Sales & Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORIIMBTMTTMBJA